- Completed GLP-validated bioanalytical method for detection of FtBu in models.
- Completed studies to determine the pharmacokinetics of FtBu following intravenous delivery of Oxycyte in models.
- Secured long-term clinical supply of GMP-grade Oxycyte ® to be used in ongoing clinical trials.
- Raised $2.5 million in second installment of Registered Direct Series A Convertible Preferred Stock financing.
- Signed a research agreement with the U.S. Navy to study using Oxycyte to treat hemorrhagic shock.
Oxygen Biotherapeutics Reports First Quarter FY2013 Financial Results
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.